Regimens and outcomes for the upfront therapy of BL
| Reference . | Regimen . | N . | Median age, y . | Risk . | TRM . | EFS/PFS . | OS . |
|---|---|---|---|---|---|---|---|
| 40 | CODOX-M/IVAC | 41 (20 adults) | 25 | High risk | 0 | 2-y EFS | |
| 83% | 92% | ||||||
| 45 | CODOX-M/IVAC | 52 | 35 | High risk | 5 | 2-y EFS | 2-y OS |
| 77% | 65% | 73% | |||||
| 46 | CODOX-M/IVAC | 53 | 37 | High risk | 9 | 2-y PFS | 2-y OS |
| 79% | 64% | 67% | |||||
| 47 | CALGB regimen | IPI ≥ 3 | 10 | 3-y EFS | 3-y OS | ||
| Cohort 1 | 52 | 44 | 55% | 52% | 54% | ||
| Cohort 2 | 40 | 50 | 45% | 50% | |||
| 48 | CALGB regimen | 105 | 44 | IPI ≥ 3 | 7 | 2-y EFS | 2-y OS |
| 47% | 74% | 78% | |||||
| 49 | HyperCVAD | 26 | 58 | High LDH | 5 | 3-y CCR | 3-y OS |
| 70% | 61% | 49% | |||||
| 41 | R-HyperCVAD | 31 | 46 | High LDH | 1 | 3-y EFS | 3-y OS |
| 100% | 80% | 89% | |||||
| 50 | LMB regimen | 72 | 33 | High LDH 60%, | 0 | 2-y EFS | 2-y OS |
| IPI ≥ 2 54% | 65% | 70% | |||||
| 51 | DA-REPOCH | 19 (HIV−) | 25 | High LDH | 0 | EFS* | OS* |
| 37% | 95% | 100% | |||||
| 51 | SC-REPOCH-RR | 11 (HIV+) | 44 | High LDH | 0 | EFS† | OS† |
| 82% | 90% | 100% |
| Reference . | Regimen . | N . | Median age, y . | Risk . | TRM . | EFS/PFS . | OS . |
|---|---|---|---|---|---|---|---|
| 40 | CODOX-M/IVAC | 41 (20 adults) | 25 | High risk | 0 | 2-y EFS | |
| 83% | 92% | ||||||
| 45 | CODOX-M/IVAC | 52 | 35 | High risk | 5 | 2-y EFS | 2-y OS |
| 77% | 65% | 73% | |||||
| 46 | CODOX-M/IVAC | 53 | 37 | High risk | 9 | 2-y PFS | 2-y OS |
| 79% | 64% | 67% | |||||
| 47 | CALGB regimen | IPI ≥ 3 | 10 | 3-y EFS | 3-y OS | ||
| Cohort 1 | 52 | 44 | 55% | 52% | 54% | ||
| Cohort 2 | 40 | 50 | 45% | 50% | |||
| 48 | CALGB regimen | 105 | 44 | IPI ≥ 3 | 7 | 2-y EFS | 2-y OS |
| 47% | 74% | 78% | |||||
| 49 | HyperCVAD | 26 | 58 | High LDH | 5 | 3-y CCR | 3-y OS |
| 70% | 61% | 49% | |||||
| 41 | R-HyperCVAD | 31 | 46 | High LDH | 1 | 3-y EFS | 3-y OS |
| 100% | 80% | 89% | |||||
| 50 | LMB regimen | 72 | 33 | High LDH 60%, | 0 | 2-y EFS | 2-y OS |
| IPI ≥ 2 54% | 65% | 70% | |||||
| 51 | DA-REPOCH | 19 (HIV−) | 25 | High LDH | 0 | EFS* | OS* |
| 37% | 95% | 100% | |||||
| 51 | SC-REPOCH-RR | 11 (HIV+) | 44 | High LDH | 0 | EFS† | OS† |
| 82% | 90% | 100% |
CALGB, Cancer and Leukemia Group B; CCR, continuous completer remission; CODOX-M/IVAC, cyclophosphamide, vincristine, doxorubicin, methotrexate, ifosfamide, etoposide, cytarabine; CVAD, cyclophosphamide, vincristine, doxorubicin, dexamethasone; DA-REPOCH, dose-adjusted rituximab, etoposide, vincristine, cyclophosphamide, doxorubicin; EFS, event-free survival; IPI, International Prognostic Index; IVAC, ifosfamide, etoposide, cytarabine; LDH, lactate dehydrogenase; LMB, lymphoma malign B; OS, overall survival; PFS, progression-free survival; SC-REPOCH-RR, short-course REPOCH with a double dose of rituximab; TRM, treatment-related mortality.
Median follow-up 86 mo.
Median follow-up 73 mo.